Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides "STATVAS"

Active, not recruiting

Phase 3 Results N/A

References

Sources for Trial Information